| Literature DB >> 36157121 |
Lajos Szakó1,2, Dávid Németh3,4, Nelli Farkas1,4, Szabolcs Kiss5,6, Réka Zsuzsa Dömötör3, Marie Anne Engh1, Péter Hegyi1,7, Balint Eross8, András Papp9.
Abstract
BACKGROUND: Previous meta-analyses, with many limitations, have described the beneficial nature of minimal invasive procedures. AIM: To compare all modalities of esophagectomies to each other from the results of randomized controlled trials (RCTs) in a network meta-analysis (NMA).Entities:
Keywords: Esophageal cancer; Esophagectomy; Laparoscopy; Minimally invasive; Network meta-analysis; Surgery
Mesh:
Year: 2022 PMID: 36157121 PMCID: PMC9403425 DOI: 10.3748/wjg.v28.i30.4201
Source DB: PubMed Journal: World J Gastroenterol ISSN: 1007-9327 Impact factor: 5.374
Figure 1Results of the selection process according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Available from: https://prisma-statement.org//prismastatement/flowdiagram.aspx.
Baseline characteristics of the included studies
|
|
|
|
|
|
|
|
|
|
|
| Straatman | 2012 | Netherlands, Spain, Italy | Multicenter | MI-TT | 59-56 | 43/16-46/17 | 62.3–61.8 | 24/35-19/36 | cT1-3, N0-1, M0 |
| van der Sluis | 2019 | Netherlands | Single center | RA-TT | 54-55 | 46/8-42/13 | 64-65 | 13/41-12/43 | T1-4a, N0-3, M0 |
| Mariette | 2019 | France | Multi center | H-TT | 103-104 | 88/15-175/32 | 59-61 (median) | 46/57-84/123 | T1-3, N0-1, M0 |
| Guo | 2013 | China | Single center | MI-TT | 111-110 | 68/43-72/38 | 57.3-60.8 | No information | T1-3, N0-1, M0 |
| Ma | 2018 | China | Single center | MI-TT | 47-97 | 36/11-83/14 | 61-59.3 | 43/0-91/2 | Resectable cancer |
| Jacobi | 1997 | Germany | Single center | TH-TT | 16-16 | No information | 54-55 | 13/3-13/3 | Resectable cancer |
| Goldminc | 1993 | Australia | Single center | TH-TT | 32-35 | 31/1-33/2 | 57.4-57.4 | 32/0-35/0 | Resectable squamous cell cancer |
| Chu | 1997 | China | Single center | TH-TT | 20-19 | 18/2-17/2 | 60.7-63.9 | No information | Lower third resectable cancer |
| Hulscher | 2002 | Netherlands | Multicenter | TH-TT | 106-114 | 92/14-97/17 | 69-64 | 0/106-0/114 | Resectable adenocarcinoma |
| Yang | 2016 | China | Single center | MI-TT | 120-120 | 82/38-87/33 | 62.5 -67.8 | 75/45-72/48 | T1-3, N0-1, M0 |
| Paireder | 2018 | Austria | Single center | H-TT | 14-12 | 10/4-10/2 | 64.5-62.5 (median) | 4/10-1/11 | Siewert I-II, resectable squamous cell cancer |
Number of patients, male/female ratio, age, and ratio of squamous cell cancer and adenocarcinoma are presented according to the compared interventional arms. H: Hybrid esophagectomy; MIE: Minimally invasive esophagectomy; RA: Robot assisted esophagectomy; TH: Transhiatal esophagectomy; TT: Transthoracic esophagectomy.
Figure 2A significant difference was found considering pulmonary infection, which favored the minimally invasive intervention compared to transthoracic surgery. A: The network of eligible studies for pulmonary infection (the width of the lines is proportional to the number of trials comparing every pair of treatments, and the size of every circle is proportional to the number of randomly assigned participants [sample size]); B: League table of the analysis for pulmonary infection. Comparisons should be read from left to right. The values are presented in risk ratios, with corresponding credible interval. Significant result is in bold and underlined; C: Cumulative probability of treatment rank; D: Treatment rank in SUCRA% histogram.
Figure 3Operation time was significantly shorter for transhiatal approach compared to transthoracic surgery, hybrid intervention, minimally invasive technique, and robot-assisted esophagectomy. A: The network of eligible studies for operation time [the width of the lines is proportional to the number of trials comparing every pair of treatments, and the size of every circle is proportional to the number of randomly assigned participants (sample size)]; B: League table of the analysis for operation time. Comparisons should be read from left to right. The values are presented in weighted mean difference (minutes), with corresponding credible interval. Significant results are in bold and underlined; C: Cumulative probability of interventions rank; D: Intervention ranking in surface under the cumulative ranking (SUCRA)% histogram.
The results of the risk of bias assessment by each domain
|
|
|
|
|
|
|
|
| Straatman | Low risk | Low risk | Low risk | Low risk | Low risk | Low risk |
| van der Sluis | Low risk | Low risk | Low risk | Low risk | Low risk | Low risk |
| Mariette | Low risk | Low risk | Low risk | Low risk | Low risk | Low risk |
| Guo | Unclear risk | Low risk | Low risk | Low risk | Unclear risk | Unclear risk |
| Ma | Unclear risk | Unclear risk | Low risk | Low risk | Unclear risk | High risk |
| Jacobi | Unclear risk | Unclear risk | Low risk | Low risk | Unclear risk | High risk |
| Goldminc | Unclear risk | Unclear risk | Low risk | Low risk | Low risk | Unclear risk |
| Chu | Unclear risk | Unclear risk | Low risk | Low risk | Unclear risk | High risk |
| Hulscher | Low risk | Unclear risk | Low risk | Low risk | Unclear risk | Unclear risk |
| Yang | Unclear risk | Unclear risk | Low risk | Low risk | Unclear risk | High risk |
| Paireder | Low risk | Unclear risk | Low risk | Low risk | Unclear risk | Unclear risk |
Risk of bias is indicated according to each domain of the Revised Cochrane risk-of-bias tool for randomized trials[23]. By the assessment of overall risk of bias, low risk of bias was given in the case of low risk of bias by every domain; if one or two domains were assessed as unclear risk of bias, unclear overall risk of bias was given, and if at least three domains were accompanied with unclear risk of bias, the overall risk of bias was assessed as high risk of bias.